<--- Back to Details
First PageDocument Content
Eli Lilly and Company / Neurological disorders / Peripheral neuropathy / Polyneuropathy / Neuropathic pain / Taxane / Vincristine / Oxaliplatin / Gemcitabine / Chemistry / Health / Medicine
Date: 2013-09-27 13:43:52
Eli Lilly and Company
Neurological disorders
Peripheral neuropathy
Polyneuropathy
Neuropathic pain
Taxane
Vincristine
Oxaliplatin
Gemcitabine
Chemistry
Health
Medicine

Add to Reading List

Source URL: www.kup.at

Download Document from Source Website

File Size: 964,32 KB

Share Document on Facebook

Similar Documents

Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th

DocID: 1uZFZ - View Document

MOLECULAR CARCINOGENESIS Taxane-Induced Hedgehog Signaling is Linked to Expansion of Breast Cancer Stem-Like Populations After Chemotherapy Jennifer Sims-Mourtada,1,2* Lynn M. Opdenaker,1, 3 Joshua Davis,1, 3 Kimberly M

DocID: 1sAC8 - View Document

RTT / Benzoates / Cancer treatments / Ribbon symbolism / Alkaloids / Docetaxel / Chemotherapy / Breast cancer / Taxane / Paclitaxel / Ovarian cancer / Pregnancy

Annals of Oncology Advance Access published August 8, 2012 review Annals of Oncology 00: 1–8, 2012 doi:annonc/mds170

DocID: 1prgZ - View Document

Cytoskeleton / Actin / Tropomyosin / Chemotherapy / Microtubule / Taxane / Docetaxel / Vinblastine / Microfilament / Cytoskeletal drugs / Discovery and development of tubulin inhibitors

ANISINA (ATMA potential new class of cytotoxic chemotherapy targeting the cytoskeleton  Preclinical studies show that Anisina enhances the killing effect of anti-microtubule drugs (taxanes and vinca alkaloids)

DocID: 1ph49 - View Document

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer Xiaochuan Shan1 , Gwenn Danet-Desnoyers1 , Juan Jos´e Fung2 , Alan H. Kosaka2 , Fraser Tan3 , Nicole Perfito3 , Joelle

DocID: 1lWYj - View Document